evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,801 questions · 4,079 findings · 473 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 669 · 16.4%GRADE not reported 852 · 20.9%Very low 738 · 18.1%Low 903 · 22.1%Moderate 716 · 17.6%High 201 · 4.9%

Mepolizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab 300 mg vs placebo

Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 300 mg vs placebo

Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 300 mg vs placebo

Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 300 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 750 mg vs placebo

Exacerbations · patients with chronic obstructive pulmonary disease

Mepolizumab 750 mg showed no clear difference in number of participants experiencing an exacerbation within 6 months compared with placebo (low certainty).

2 findings from 1 review